8 июн. 2023 г. · 1. Indications of TACE follow the 2022 KLCA-NCC Korea practice guidelines for the management of HCC, and a personalized approach regarding tumor ...

Transarterial chemoembolization (TACE) is the standard of care for patients with intermediate stage hepatocellular carcinoma. (BCLC B).

The purpose of TACE for patients with HCC is to locally control or shrink the tumor. Several previous studies demonstrated that the repetition of cTACE ...

With regards to HCC, indications for TACE follow the. Barcelona Clinic Liver Cancer (BCLC) recommendations. They have recently been amended to include Stages 0- ...

The following Clinical Practice Guidelines will give up-to-date advice for the clinical management of patients with hepatocel- lular carcinoma, as well as ...

Transarterial chemoembolization (TACE) is the standard of care for patients with intermediate stage hepatocellular carcinoma (BCLC B).

Taiwanese guidelines recommend the HCC surveillance interval with a range of 6–12 months.

TACE should be considered as the first-line liver-directed treatment for patients with BCLC intermediate-stage HCC who are suitable for liver-directed therapy.

In limited experience, transarterial chemoembolization has been found to be effective in management of larger tumors and as adjuvant therapy for HCC resection.

5 мар. 2021 г. · Updated treatment recommendations for hepatocellular carcinoma (HCC) from the ESMO Clinical Practice Guidelines. Published: 05 March 2021.